Patents by Inventor Alan Borthwick

Alan Borthwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminoindane Compounds and Compositions and Methods of Their Therapeutic Use
    Publication number: 20260159474
    Abstract: The present invention discloses therapeutic compounds of the aminoindane class, including certain short-acting ester and lactone derivatives, and pharmaceutical compositions made therewith, as well as methods of their use in the treatment of alcohol and other substance use disorders, behavioral addictions, and CNS and mental health disorders, and for the improvement of mental health and psychological functioning.
    Type: Application
    Filed: September 10, 2025
    Publication date: June 11, 2026
    Inventors: David Nutt, Alan Borthwick
  • Morpholine-like monoamine releasers
    Patent number: 12595269
    Abstract: Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such compounds, and methods of their use to treat mental health disorders and CNS disorders.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: April 7, 2026
    Assignee: Solvonis Therapeutics Ireland Holdings Limited
    Inventors: Alan Borthwick, Fabrizio Micheli, Alessandra Micoli, Ferruccio Palazzesi, Agostino Cianciulli, Robin Tyacke, David Nutt
  • Short-acting monoamine releasers
    Patent number: 12590077
    Abstract: Disclosed herein are novel 1,3-benzodioxole esters and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such 1,3-benzodioxole esters, and methods of their use to treat CNS disorders, and in particular mental health disorders.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: March 31, 2026
    Assignee: Solvonics Therapeutics Ireland Holdings Limited
    Inventors: David Nutt, Alan Borthwick, Robin Tyacke
  • BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS
    Publication number: 20250179089
    Abstract: Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such compounds, and methods of their use to treat mental health disorders and CNS disorders.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 5, 2025
    Inventors: Alan Borthwick, Fabrizio Micheli, Alessandra Micoli, Ferruccio Palazzesi, Agostino Cianciulli, Robin Tyacke, David Nutt
  • 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE
    Publication number: 20250100990
    Abstract: Disclosed herein are novel 1,3-benzodioxole esters and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such 1,3-benzodioxole esters, and methods of their use to treat CNS disorders, and in particular mental health disorders.
    Type: Application
    Filed: January 19, 2023
    Publication date: March 27, 2025
    Inventors: David Nutt, Alan Borthwick, Robin Tyacke
  • THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS
    Publication number: 20240190809
    Abstract: The present invention discloses therapeutic compounds of the aminoindane class, including certain short-acting ester and lactone derivatives, and pharmaceutical compositions made therewith, as well as methods of their use in the treatment of alcohol and other substance use disorders, behavioral addictions, and CNS and mental health disorders, and for the improvement of mental health and psychological functioning.
    Type: Application
    Filed: May 11, 2022
    Publication date: June 13, 2024
    Inventors: David Nutt, Alan Borthwick
  • Piperazinediones as Oxytocin Receptor Antagonists
    Publication number: 20070254888
    Abstract: Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    Type: Application
    Filed: June 21, 2005
    Publication date: November 1, 2007
    Applicant: GLAXO GROUP LIMITED
    Inventors: Alan Borthwick, Deirdre Mary Hickey, John Liddle, Andrew Mason
  • Substituted Diketopiperazines as Oxytocin Antagonists
    Publication number: 20070208031
    Abstract: Compounds of formula (IA) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 1-methyl-indazol-5-yl, R4 represents methyl and R5 represents hydrogen or methyl, and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    Type: Application
    Filed: June 21, 2005
    Publication date: September 6, 2007
    Inventors: Alan Borthwick, Steven Sollis
  • 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors
    Publication number: 20070203206
    Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof.
    Type: Application
    Filed: July 17, 2004
    Publication date: August 30, 2007
    Inventors: Alan Borthwick, Savvas Kleanthous, Stefan Senger, Ian Smith
  • Substituted diketopiperazines as oxytocin receptor antagonists
    Publication number: 20070185162
    Abstract: Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-ethylpropyl, R3 is a heterocyclic group optionally substituted by one or more C1-6 alkyl groups, R4 represents methyl and R5 represents hydrogen or methyl and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    Type: Application
    Filed: June 21, 2005
    Publication date: August 9, 2007
    Applicant: Koninklijke Philips Electronics, N.V.
    Inventors: Alan Borthwick, Deidre Mary Hickey, John Liddle, Andrew Mason, Derek Pollard, Steven Sollis
  • 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa
    Publication number: 20060178419
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Application
    Filed: June 17, 2004
    Publication date: August 10, 2006
    Applicant: GLAXO GROUP LIMITED
    Inventors: Alan Borthwick, John Harling, Wendy Irving, Savvas Kleanthous, Nigel Watson, Robert Young
  • Pyrrolidine -2-ones as factor xa inhibitors
    Publication number: 20060167079
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Application
    Filed: July 17, 2004
    Publication date: July 27, 2006
    Inventors: Alan Borthwick, Henry Kelly, Nigel Watson, Robert Young
  • Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa
    Publication number: 20060166985
    Abstract: The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 27, 2006
    Inventors: Alan Borthwick, Chuen Chan, Henry Kelly, Simon Peace, Stefan Senger, Gita Shah, Stefan Smith, Steven Smith, Nigel Watson, Robert West, Robert Young
  • 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases
    Publication number: 20060148879
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Application
    Filed: June 17, 2004
    Publication date: July 6, 2006
    Inventors: Alan Borthwick, Chuen Chan, Henry Kelly, Savvas Kleanthous, Andrew Mason, Nigel Watson
  • Substituted diketopiperazines as oxytocin antagonists
    Publication number: 20050148572
    Abstract: A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.
    Type: Application
    Filed: December 20, 2002
    Publication date: July 7, 2005
    Inventors: Alan Borthwick, Richard Hatley, Deirdre Hickey, John Liddle, David Livermore, Andrew Mason, Neil Miller, Fabrizio Nerozzi, Steven Sollis, Anna Szardenings, Paul Wyatt
  • Pyrrolidine-2-ones as factor xa inhibitors
    Publication number: 20050059726
    Abstract: The present invention relates to novel compounds and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and to the use of compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: December 20, 2002
    Publication date: March 17, 2005
    Inventors: Alan Borthwick, Chuen Chan, Henry Kelly, Nigel King, Savvas Kleanthous, Andrew Mason, Ivan Pinto, Derek Pollard, Stefan Senger, Gita Shah, Nigel Watson, Robert Young
  • 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
    Publication number: 20050004119
    Abstract: The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.
    Type: Application
    Filed: November 13, 2002
    Publication date: January 6, 2005
    Inventors: Alan Borthwick, Matthew Campbell, Chuen Chan, Henry Kelly, Nigel King, Savvas Kleanthous, Andrew Mason, Stefan Senger, Paul Smith, Nigel Watson, Robert Young